You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

High levels of MicroSatellite Instability deficient MisMatch Repair (MSI-H-dMMR) tumor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial in ZhengZhou (Cadonilimab

Not yet recruiting
  • Colorectal Cancer
  • +3 more
  • Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody
  • ZhengZhou, Henan, China
    Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
Jun 18, 2023

Adenocarcinoma - GEJ, Gastric Adenocarcinoma Trial (Dostarlimab)

Not yet recruiting
  • Adenocarcinoma - GEJ
  • Gastric Adenocarcinoma
  • (no location specified)
Sep 26, 2023

Colorectal Cancer Trial in Beijing (IBI310 (anti-CTLA-4 antibody), Sintilimab(anti-PD-1 antibody))

Active, not recruiting
  • Colorectal Cancer
  • IBI310 (anti-CTLA-4 antibody)
  • Sintilimab(anti-PD-1 antibody)
  • Beijing, China
    Beijing cancer hospital
Sep 15, 2022

Colorectal Carcinoma Trial (mFOLFOX6, FOLFIRI, pembrolizumab)

Active, not recruiting
Has Results
  • Colorectal Carcinoma
  • (no location specified)
Oct 28, 2022

Colorectal Cancer Stage IV, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial (Cadonilimab)

Not yet recruiting
  • Colorectal Cancer Stage IV
  • +2 more
  • (no location specified)
Jun 19, 2022

Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial in Guangzhou (Neoadjuvant

Recruiting
  • Colorectal Cancer
  • +3 more
  • Neoadjuvant therapy with PD-L1 inhibitor
  • Guangzhou, Guangdong, China
    the Third Affiliated Hospital of Sun Yat-Sen University
May 10, 2022

DOstarlimab in Recurrent or dMMR/MSI-H Endometrial Cancer

Not yet recruiting
  • Endometrial Cancer
  • (no location specified)
Feb 14, 2023

Multiple Cancer, Colorectal Cancer Trial (MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 mAb neoadjuvant

Not yet recruiting
  • Multiple Cancer
  • Colorectal Cancer
  • MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy
  • All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy
  • (no location specified)
Aug 20, 2023

Advanced Solid Tumors Trial (RO7589831)

Not yet recruiting
  • Advanced Solid Tumors
  • (no location specified)
Aug 16, 2023

MSI-H/dMMR Solid Tumor Trial in Guangzhou (AK104)

Terminated
  • MSI-H/dMMR Solid Tumor
  • Guangzhou, Guangdong, China
    Sun Yat-Sen University Cancer Center
Oct 17, 2022

Registry Study in MSI/dMMR Solid Tumors

Not yet recruiting
  • DMMR Cancer
  • +2 more
    • (no location specified)
    Aug 21, 2023

    MSI-H Trial in Guangzhou (IBI310, Radical surgery, Sintilimab)

    Not yet recruiting
    • MSI-H
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    May 26, 2023

    Colorectal Carcinoma Trial in Guangzhou (Sintilimab, Oxaliplatin, capecitabine)

    Recruiting
    • Colorectal Carcinoma
    • Guangzhou, China
      Sun Yat-sen University
    Dec 29, 2022

    MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers Trial in Kashiwa (HRO761,

    Recruiting
    • MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
    • Kashiwa, Chiba, Japan
      Novartis Investigative Site
    May 2, 2023

    Metastatic Colorectal Cancer Trial in China (HX008, Investigator's Choice Chemotherapy)

    Not yet recruiting
    • Metastatic Colorectal Cancer
    • HX008
    • Investigator's Choice Chemotherapy
    • Hefei, Anhui, China
    • +9 more
    Dec 8, 2022

    Solid Tumor Trial in Beijing (KN035)

    Recruiting
    • Solid Tumor
    • KN035
    • Beijing, Beijing, China
      Peking University Cancer Hospital, Peking University
    Apr 5, 2022

    Melanoma, Hepatocellular Carcinoma (HCC), Renal Cell Carcinoma (RCC) Trial (INCB 99280 with Ipilimumab)

    Not yet recruiting
    • Melanoma
    • +5 more
    • INCB 99280 with Ipilimumab
    • (no location specified)
    Jun 9, 2023

    Colorectal Cancer Trial in China (Tislelizumab)

    Recruiting
    • Colorectal Cancer
    • Bengbu, Anhui, China
    • +7 more
    Sep 13, 2022

    Colon Cancer Trial (Tislelizumab)

    Not yet recruiting
    • Colon Cancer
    • (no location specified)
    Feb 7, 2022

    Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult Trial (NEO212 Oral Capsule, Ipilimumab,

    Not yet recruiting
    • Diffuse Astrocytoma, IDH-Mutant
    • +20 more
    • NEO212 Oral Capsule
    • +8 more
    • (no location specified)
    Sep 18, 2023

    Melanoma Stage IV, Unresectable Melanoma, NSCLC Stage IV Trial in Ramat Gan (Fecal Microbial Transplantation by capsules)

    Recruiting
    • Melanoma Stage IV
    • +2 more
    • Fecal Microbial Transplantation by capsules
    • Ramat Gan, Israel
      Sheba Medical Center
    Aug 9, 2021

    Localized Oesogastric Adenocarcimona, MSI and or dMMR Trial in France (Nivolumab 10 MG/ML, Ipilimumab 200 MG in 40 ML Injection)

    Recruiting
    • Localized Oesogastric Adenocarcimona
    • MSI and or dMMR
    • Nivolumab 10 MG/ML
    • Ipilimumab 200 MG in 40 ML Injection
    • Besançon, France
    • +14 more
    Jun 10, 2021

    The mCRC pMMR/MSS or dMMR/MSI-H Status Received Palliative

    Completed
    • Colorectal Cancer Metastatic
    • +2 more
      • Guangzhou, Guangdong, China
        Sun yat-sen university cancer center
      Jul 23, 2020

      Endometrial Cancer Trial in United States (Intensity modulated radiation therapy (IMRT), Dostarlimab)

      Recruiting
      • Endometrial Cancer
      • Basking Ridge, New Jersey
      • +6 more
      Jul 5, 2022

      Colorectal Cancer Trial in Worldwide (Pembrolizumab, Pembrolizumab/Quavonlimab, Pembrolizumab/Favezelimab)

      Recruiting
      • Colorectal Cancer
      • Pembrolizumab
      • +4 more
      • Orange City, Florida
      • +54 more
      Aug 17, 2022